Methylation of SRD5A2 in the Blood as a Novel Biomarker to Predict Sensitivity to 5-ARI Treatment
April 2024
in “
The Journal of urology/The journal of urology
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → 
Studysummary In this study, researchers found that methylation of the SRD5A2 gene in blood and tissue samples can serve as a biomarker to predict men's clinical response to finasteride treatment for benign prostatic hyperplasia, offering a non-invasive method for assessing potential treatment success. Our plain-language summary of this paper — not a Tressless recommendation.
This study investigates the potential of using SRD5A2 methylation as a biomarker to predict the response to finasteride treatment in men with benign prostatic hyperplasia (BPH). The research involved 83 patients from the MTOPS trial and 11 participants from a clinical trial at the authors' institution. Results showed that good responders to finasteride had higher SRD5A2 protein expression, while poor responders had lower expression. Additionally, SRD5A2 protein expression was negatively correlated with prostate tissue methylation and positively correlated with peripheral WBC methylation and ferumoxytol uptake on MRI. These findings suggest that assessing SRD5A2 methylation in peripheral WBCs or using ferumoxytol-enhanced MRI could serve as non-invasive methods to predict finasteride treatment response.
